Drop in PSA Tied to Better Outcomes of Apalutamide Therapy in Prostate Cancer

Drop in PSA Tied to Better Outcomes of Apalutamide Therapy in Prostate Cancer

Comments

Post a Comment

Popular posts from this blog

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

Image
  Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
Read more

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more

What to Expect and Plan for in Pluvicto Treatment at UCSD:

Image
What to Expect and Plan for in Pluvicto Treatment: A Comprehensive Guide for Prostate Cancer Patients Special Report for the IPCSG Newsletter Major FDA Expansion Opens Treatment to More Patients On March 28, 2025, the FDA expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay chemotherapy. This expanded indication approximately triples the number of patients eligible to receive Pluvicto. This groundbreaking development means that many more patients can now access this innovative treatment earlier in their disease progression, potentially before requiring chemotherapy. Understanding Pluvicto: How It Works Pluvicto is a "theranostic" medicine that combines diagnostic and therapeutic capabilities. It's a type of radiation that specif...
Read more